Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Thaminda Ramanayake as Chief Business Officer. Mr. Ramanayake is a business development and transactions specialist who has spent over a decade working to bring value to patients globally and has a strong track record in company creation, in/out-licensing, M&A, joint ventures and cross-border transactions.
